BIOLASE - Mit GEWINN INS NEUE JAHR - 500 Beiträge pro Seite

[tapello]

Wer weiß mehr über Biolase. Ist zur Zeit spottbillig und schreibt für das nächste Jahr schwarzer Zahlen.
Wo findet man mehr Infos?

[Devine]

Hi,
woher weisst du das mit den schwarzen Zahlen

im übrigen gibts hier ne Suchfunktion.

Grüsse,
Devinchen

[luna2000]

firmenbilanz und umsaetze unter www.onvista.de!
schoenes neues jahr euch allen!

[tapello]

das mit den schwarzen Zahlen steht auf der
Seite von Finance-online.Meldung vom 28.12.2000

[tapello]

Oh sorry, von schwarzen Zahlen steht hier doch nichts, nur das es für nächstes Jahr ganz gut aussieht.
Biolase erstmals mit Gewinn
Hier ist der Bericht:

Die Biolase Technology Inc., ein Unternehmen für medizinische und dentale Technologien, gab am heutigen Donnerstag bekannt, dass seine Umsatzzahlen für das dritte Quartal die $3 Millionengrenze überschreiten werden. Im letzten Jahr waren es noch $1.8 Millionen.
Das Unternehmen gab in einer öffentlichen Stellungnahme bekannt, dass man den Break-Even-Point, also die Gewinnschwelle, erreicht habe und einen leicht positiven Cash-Flow im vierten Quartal erwarte.

Desweiteren äusserte man sich zu dem starken Fall der Aktie um 31 Prozent und stellte ihn als unbegründet hin. Der Präsident und CEO Jeffrey W. Jones meinte, dass die Absatzzahlen des neuen Biolase Waterlase Dentallasers für schmerzloses Bohren und Operieren sehr hoch seien.

[WG_2011]

Hallo zusammen,

ich habe vor kurzem diesen Thred entdeckt und gestern ein längeres posting getippt. Leider ist dieses im digitalen Nirwana verschwunden. Sinngemäß, aber kurz:
Ich bin Dentaltechniker
Ich warte und repariere Lasergeräte
Ich wurde 1998 für das Vorgängermodell geschult
Die Geräte wurden nach zwei Jahren voller Probleme vom deutschen Markt zurückgezogen
Ich habe persönlichen Kontakt zu Mitarbeitern von Biolase gehabt und war von deren Überheblichkeit nicht angetan
Ich wäre bei diesem Verein vorsichtig
Technische Information gerne unter [e-mail]

Gruß WG

[tapello]

danke für die Infos.
ich bin auch nicht eingestiegen.

[Skydiver-]

Heute FDA Marktzulassung fuer TWILITE Laser-Zahnweisser. Kurs in FSE steigt bei Riesenumsaetzen (15 Stk.=42 €!).

[Skydiver-]

Sieht ja schon besser aus.

[Pega]

Hi Börsenneulinge, nach dem heutigen EamS-Bericht über Biolase nicht in Deutschland unlimitiert kaufen! Ihr erlebt sonst Euer blaues Wunder! Versucht es lieber direkt in den USA!

[MicroSnake]

BIOLASE to Release Financial Results, Hold Conference Call on March 1
SAN CLEMENTE, Calif., Feb. 28 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), will release its fourth quarter and year-end financial results on Thursday, March 1, 2001.

A conference call will also be held on March 1 at 11:00 A.M. EST, during which the company will review the results and other recent developments.

Those who wish to participate in the conference call may telephone [phone] approximately 15 minutes before the 11:00 A.M. starting time. A replay will be available by telephone for 10 days at [phone] toll free in the United States or [phone] for international callers.

BIOLASE Technology, Inc., (www.BIOLASE.com) is an advanced medical technology company, which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase(TM) (HydroKinetic®) surgical cutting systems and other advanced laser- and non-laser-based products for the professional and consumer markets. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard- and soft-tissue dental laser technology.

The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Actual results may differ materially from those projected. These forward-looking statements represent the company`s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

For further information, please contact L. B. Stauffer, Sr. VP, or Leighton Foster, Investor Relations, of Porter, LeVay & Rose, Inc., 212-564-4700, for BIOLASE Technology, Inc.; or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc., 949-361-1200.

[MicroSnake]

BIOLASE Reports Record Fourth Quarter and Annual Results for 2000
SAN CLEMENTE, Calif., March 1 /PRNewswire/ -- BIOLASE TECHNOLOGY, INC. (Nasdaq: BLTI - news), today announced a 105% increase in sales, a 231% increase in gross profit with gross margins growing from 38% to 61% and a 68% decrease in net loss for its fourth quarter of operations ended December 31, 2000 compared with the same period in 1999.

The Company continued strong growth with record sales of $3,684,389 and $9,657,389 for its fourth quarter and fiscal year ended December 31, 2000, respectively, reflecting increases of $1,885,179, or 105%, and $2,653,117, or 38%, compared to sales of $1,799,210 and $7,004,272 for the 1999 fourth quarter and fiscal year. The Company`s net loss decreased in the fourth quarter of 2000 to $643,391, or 3 cents per basic/diluted share, from the $2,008,250, or 11 cents per basic/diluted share, reported for the same period in 1999. The Company also generated positive cash flow from operations in excess of $600,000 during the fourth quarter of 2000.

The increase in sales for the fourth quarter and fiscal year 2000 over the same periods in 1999 were a direct result of the marketing by the Company coupled with the progression from the original Millennium to the introduction of the new and more technically advanced Waterlase and Twilite laser systems, both launched in quantity during the third quarter of 2000.

Gross profit for the fourth quarter of 2000 increased $1,570,926, or 231%, to $2,251,181, or 61% of sales, compared to $680,255, or 38% of sales, for the same period in 1999. Fiscal year 2000 gross profit was $4,828,361, or 50% of sales, reflecting an increase of $1,975,835, or 69%, from $2,852,526, or 41% of sales, for fiscal year 1999. The increase in gross profit for the fourth quarter of 2000 over that reported for the same period in 1999 was due principally to engineered cost reductions and higher volumes.

Sales and marketing expense for the fourth quarter of 2000 was $1,738,272 compared to $829,918 for the same period in 1999, an increase of $908,354, or 109%. General and administrative expense for the fourth quarter of 2000 decreased $421,827, or 46%, to $503,823 from the $925,650 reported for the same period in 1999. Absent certain non-recurring charges of $480,000 included within general and administrative expense for the 1999 fourth quarter, the Company would have reported an increase in such expense of $58,173, or 13%. Engineering and development expense decreased $324,378, or 35%, to $594,710 for the fourth quarter of 2000 from the $919,088 reported for the same period in 1999. On a comparative basis, engineering and development expense for the fourth quarter of 2000 would have reflected an increase of $58,035, or 11%, absent a $382,413 non-recurring charge included in the fourth quarter of 1999.

Sales and marketing expense for fiscal 2000 was $4,333,346 compared to $2,700,628 reported for fiscal 1999, an increase of $1,632,718, or 60%. The increase was due principally to market development expense including a broad expansion of the Company`s domestic sales force and its marketing infrastructure. General and administrative expense for fiscal 2000 decreased $631,594, or 26%, to $1,840,950 compared to the $2,472,544 reported for fiscal 1999. Absent $609,981 in non-recurring charges included in fiscal 1999, general and administrative expense for 2000 would reflect a nominal decrease of $21,613, or 1% compared to fiscal 1999. Engineering and development expense decreased $140,007, or 6%, to $2,287,503 in fiscal 2000 compared to the $2,427,510 reported for fiscal 1999. After consideration of the $483,194 of non-recurring charges included in fiscal 1999, engineering and development expense for fiscal 2000 would have reflected an increase of $343,187 or 18% over fiscal 1999.

Jeffrey W. Jones, BIOLASE CEO and president, commented, ``These record results reflect the beginnings of a growing demand for our dental laser technology. The dental laser market today is where the ophthalmic, medical and cosmetic laser markets were in the early nineties. Lasers are commonplace for today`s ophthalmologists, dermatologists and cosmetic surgeons. It is the common belief by dentists using the Waterlase, that this technology will be routinely used in dentistry in a few short years. The difference is, with 540,000 dentists in the developed countries, a mere 3% market penetration would result in more than half a billon dollars in sales at our current average sales price. It is very important to consider that the potential dental market is by far larger than all other medical laser markets combined.``

``During the past two years, BIOLASE has made significant and continuing progress. We have moved from being a minor player in the embryonic new dental laser market in 1998 to the respected position of the world leader in this promising and rapidly expanding market.``

Jones continued, ``In addition to increasing sales, our innovative product development has resulted in sharp cost reductions while improving the product. Our R&D efforts to further reduce production costs while improving our laser products will continue. It has taken a lot of hard work, but as the public is becoming increasingly aware of the superior clinical benefits of the Waterlase patented technology, we will see more and more dentists purchasing the system to offer their patients a higher standard of care and pain free procedures.

``Our clinical directors, Ioana Rizoiu, M.S. and William Vitale, DMD, have recently developed expanded applications for the product to perform root canal, periodontal, cosmetic and whitening treatments. These new expansions of our existing products into the endodontic and cosmetic markets dramatically expand the market for products. During 2000 and Q1 of 2001, BIOLASE received important new patents and FDA clearances, strengthening our product portfolio.

``We are recognizing and pursuing additional markets for our existing technologies as evidenced by our recent entrance into the veterinarian market. We are properly allocating our resources by having our distributor provide all of the sales force and marketing expenses for this new market.``

``The progress that BIOLASE has achieved has been recognized by many prestigious organizations including Dateline, MSNBC and CNBC. In 2000, BIOLASE was awarded the Technology Fast 50 Award for Southern California. In January 2001, the Waterlase was on the cover the Dentistry Today, a leading dental journal. Additionally, in the near future, BIOLASE will be on the cover of Dental Products Report and Dental Town, both leading dental publications. National and international media coverage of the Waterlase continues to increase on television news programs, consumer publications and numerous dental trade journals. ``

Jones continued, ``In addition to the strength of our technology, I credit our success to date to our dedicated team of professionals. Everyone at BIOLASE, from R&D, production and manufacturing, field service engineers and our talented sales force, has contributed to the successful year we had in 2000. We will continue to build and strengthen our team to accelerate our growth.``

Jones concluded, `` 2001 is off to a good start and we expect first quarter results to show a strong increase over the same period of 2000. Aggressive marketing, high growth in sales and profitability is our mission for 2001. With our strong patented technology and market presence, we believe we will be able to lead this high growth market for years to come.``

BIOLASE Technology, Inc. (http://www.biolase.com) is an advanced medical technology company which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase (HydroKinetic) surgical cutting systems and other advanced laser and non-laser based products for the professional and home consumer market. The Company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard and soft tissue dental laser technology.

The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the Company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.


BIOLASE TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEETS


December 31,
2000 1999

Assets:
Current assets:
Cash and cash equivalents $2,001,884 $1,180,982
Accounts receivable, less allowance
of $120,988 in 2000 and $117,745 in 1999 758,219 330,840
Inventories, net of reserves
of $449,597 in 2000 and $309,420 in 1999 1,221,595 658,462
Prepaid expenses and other current assets 179,985 110,062

Total current assets 4,161,683 2,280,346

Property, plant and equipment, net 2,329,305 203,529
Patents, trademarks and licenses,
less accumulated amortization of
$174,077 in 2000 and $151,278 in 1999 104,158 126,958
Other assets 3,954 61,480

Total assets $6,599,100 $2,672,313


Liabilities and Stockholders` Equity (Deficit):
Current liabilities:
Current portion of long-term debt $20,486 $--
Line of credit 1,791,925 1,341,925
Accounts payable 945,873 792,073
Customer deposits 200,000 --
Accrued expenses 1,409,367 997,287
Accrued expenses related to the
reacquisition of foreign
distribution rights -- 480,300

Total current liabilities 4,367,651 3,611,585

Long-term debt, net of current portion 1,174,578 --

Total liabilities 5,542,229 3,611,585

Stockholders` equity (deficit):
Preferred stock, par value $.001,
1,000,000 shares authorized:
no shares issued and outstanding
in 2000 or 1999 -- --
Common stock, par value, $.001,
50,000,000 shares authorized,
issued 19,366,522 in 2000 and
17,583,305 in 1999 19,367 17,583

Additional paid-in capital 47,532,026 41,809,690
Accumulated deficit (46,494,522) (42,766,545)

Net stockholders` equity (deficit) 1,056,871 (939,272)

Total liabilities and
stockholders` equity (deficit) $6,599,100 $2,672,313


BIOLASE TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS


Three Months Ended Twelve Months Ended
December 31, December 31,
2000 1999 2000 1999

Sales $3,684,389 $1,799,210 $9,657,389 $7,004,272
Cost of sales 1,433,208 1,118,955 4,829,028 4,151,746

Gross profit 2,251,181 680,255 4,828,361 2,852,526

Operating expenses:
Sales and
marketing 1,738,272 829,918 4,333,346 2,700,628
General and
administrative (1) 503,823 925,650 1,840,950 2,472,544
Engineering and
development (2) 594,710 919,088 2,287,503 2,427,510

Total operating
expenses 2,836,805 2,674,656 8,461,799 7,600,682

Loss from
operations (585,624) (1,994,401) (3,633,438) (4,748,156)

Other income (expense)
Interest income 11,324 8,455 68,854 44,666
Interest expense (69,091) (22,304) (163,393) (93,647)

Net loss $(643,391) $(2,008,250) $(3,727,977) $(4,797,137)

Loss per share -
basic and diluted $(0.03) $(0.11) $(0.19) $(0.28)

Weighted average
shares
outstanding 19,336,359 17,561,985 19,170,863 17,254,005


(1) Includes $480,000 and $609,981 of non-recurring costs for the
three and twelve months ended December 31, 1999, respectively.

(2) Includes $382,413 and $483,194 of non-recurring costs for the
three and twelve months ended December 31, 1999, respectively.


For further information, please contact Elisa Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, or Larry Stauffer, Sr. VP, of Porter, LeVay & Rose, Inc., 212-564-4700, for BIOLASE Technology, Inc.; or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc., 949-361-1200.

SOURCE: BIOLASE Technology, Inc.

[weitsicht]

Hier ein paar Infos aus der SANGUI-Infomappe für Anleger.

Marktpotential in US-Dollar,also der ganze Kuchen.

Künstlicher Sauerstoffträger:

Blut-Substitut:US-Markt 1,5 Mrd.; weltweit: 3 Mrd.

Blut-Additivs: 6 Mrd. weltweit.

SANGUI entwickelt ausserdem noch künstliches Blut mit

einem geschätzdem Marktvolumen von weltweit 14 Mrd.Dollar,

ein harter Kampf um die Maktanteile wird erwartet.

Hautpflegemittel, deutscher Markt : 4 Mrd DM

Medizinische Kosmetik, deutscher Markt : 1,15 Mrd. DM

Anti-Aging Produkte,deutscher Markt:dreistellige Millionen-
Betrag.

Glukosesensor:

Sehr vorsichtige Schätzung seitens SANGUI.

Bei 500.000 Sensoren pro Jahr und 7500 us$ pro Stück

jährliches Potential von 3,75 Mrd US-Dollar.

Künstliche Beta-Zelle (Sensor+Insulinpumpe):

Marktpotential bei einem Abnehmerkreis von 10% und einem

Preis pro Stück 10.000 US$ etwa 4,5 Mrd Dollar.



In Kooperation mit CompMess GmbH&Co.KG, hat SANGUI ein

neues Durchfluss-Analysesystem entwickelt und zum

Patent beim Deutschen Patentamt eingereicht.


SANGUI hat im Jahr 2000 allein 15 Patente zur Anmeldung

gebracht.

[MicroSnake]

BIOLASE Expects Sales Growth of at Least 75% for Q1
SAN CLEMENTE, Calif., March 22 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), announced that it is experiencing strong sales growth for the first quarter of 2001. BIOLASE expects sales to increase at least 75% for the first quarter of 2001 compared to the same period in 2000. BIOLASE also commented that its does not know of any reason for the weakness in its stock price.

Jeffrey W. Jones, BIOLASE president and CEO, commented, ``We are extremely pleased to continue experiencing such strong sales growth. Our new products, the Waterlase(TM) and Twilite(TM) dental lasers, are being very well received by the market. We are seeing a significant increase in closure rates compared to a year and even six months ago.``

Jones continued, ``We expect to have another outstanding year in 2001. We also believe that the current economic slowdown will not negatively affect our overall growth since the dental community is now positively embracing the need to our painless laser technology. Patients will continue to seek out the best dental care, even in a weak economy.``

Jones concluded, ``We are very enthusiastic about our business and look forward to several years of very strong sales growth for our company as we continue our aggressive and deeper penetration of the dental market.``

BIOLASE Technology, Inc., (www.BIOLASE.com) is an advanced medical technology company, which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase (HydroKinetic®) surgical cutting systems and other advanced laser- and non-laser-based products for the professional and consumer markets. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard- and soft-tissue dental laser technology.

The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

For further information please contact: Elisa Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, or Larry Stauffer, Sr. VP, all of Porter, LeVay & Rose, Inc., 212-564-4700, for BIOLASE Technology, Inc.; or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc., 949-361-1200

[MicroSnake]

BioLase sees 75 pct sales growth in Q1
SAN CLEMENTE, Calif., March 22 (Reuters) - BioLase Technology Inc. (NasdaqSC:BLTI - news), a medical and dental technology company, on Thursday said it saw sales growth of at least 75 percent in the first quarter.

``We expect to have another outstanding year in 2001,`` said BioLase president and chief executive officer, Jeffrey Jones in a release. ``We also believe that the current economic slowdown will not negatively affect our overall growth.``

The company also said it knew of no reasons for weakness in its stock price.

Shares of the San Clemente, Calif.-based company closed at $1-9/16 on the Nasdaq stock market on Wednesday, at the low end of a 52-week range of $4-3/8 to $1.

[DerStaatsanwalt]

Habe Biolase im letzten jahr verkauft, die Aktie will keiner
Legt euch nicht so einen Mist rein.
Vertex, Protein design kaufen

[MicroSnake]

April 02, 2001

BIOLASE TECHNOLOGY INC (BLTI)
Annual Report (SEC form 10-K)
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS


Results of Operations - 2000 as Compared to 1999

Sales continued to grow during 2000 to $9,657,389 from the $7,004,272 reported during 1999, an increase of $2,653,117, or 38%, representing another new sales record for the Company. Export sales increased to $4,189,059 during 2000 compared to $2,356,000 during 1999, an increase of $1,833,059, or 78%. Domestic sales were $5,468,330 for 2000, reflecting an increase of $820,330, or 18%, from the $4,648,272 reported for 1999. The increase in sales was due principally to sales and marketing coupled with the progression from the original Millennium(R) version to the new, more advanced Waterlase(TM) system and the introduction of the new Twilite(TM) diode laser system, both launched in quantity during the third quarter of 2000. Successful alliances with synergistic international distributors have contributed to the increase in export sales.

During 2000, the Company recommenced sales to Germany through its new German distributor. Management believes the German selling market represents one of its, if not the single, largest selling market in Europe. The Company also commenced sales in France, Korea, Taiwan and Japan during 2000 and, with the recommencement in Germany, all contributed to the increase in export sales during 2000 over those in 1999.

Gross profit during 2000 increased $1,975,835, or 69%, to $4,828,361, or 50% of sales, compared to $2,852,526, or 41% of sales, for 1999. The improvement in the gross margin was due principally to increased sales volume combined with the improved design of the Waterlase(TM) system, allowing for lower material costs and increased manufacturing efficiencies. The introduction of the Company`s Twilite(TM) diode laser system also contributed to the higher gross profit.

Operating expenses were $8,461,799 for 2000 compared to $7,600,682 in 1999, an increase of $861,117, or 11%. Absent $1,093,175 of non-recurring charges included in 1999, operating expenses in 2000 would have reflected an increase of $1,954,292, or 30%, over those reported comparatively in 1999.

Sales and marketing expense during 2000 was $4,333,346 compared to $2,700,628 for 1999, an increase of $1,632,718, or 60%. The increase was due principally to (i) higher sales volume, (ii) expansion of the Company`s domestic sales force and marketing infrastructure, (iii) increased marketing and advertising, and (iv) teaching and educational seminars and activities promoting the Company`s products, both domestically and abroad.

General and administrative expense for 2000 decreased $631,594, or 26%, to $1,840,950 compared to the $2,472,544 reported for 1999. Absent $609,981 in non-recurring charges included in 1999, general and administrative expense for 2000 would reflect a nominal decrease of $21,613, or 1% compared to 1999.

Engineering and development expense decreased $140,007, or 6%, to $2,287,503 in 2000 compared to the $2,427,510 reported for 1999. After consideration of $483,194 of non-recurring charges included in fiscal 1999, engineering and development expense for fiscal 2000


would have reflected an increase of $343,187, or 18%, over fiscal 1999. The increase was due principally to ongoing product development.

Interest income increased nominally to $68,854 during 2000 from the $44,666 reported for 1999 due principally to higher average cash balances maintained in interest-bearing accounts over the previous year. Interest expense was $163,393 in 2000 compared to $93,647 for 1999, an increase of $69,746, or 75%. The increase was due principally to a higher average balance during 2000 in the Company`s line of credit than that in 1999.


Results of Operations - 1999 as Compared to 1998

Sales for 1999 increased $5,539,081, or 378%, to $7,004,272 from the $1,465,191 reported for 1998 representing the highest reported sales in the Company`s history. Export sales were $2,356,000 during 1999 compared to $598,000 during 1998, an increase of $1,758,000, or 294%. Domestic sales increased $3,781,081, or 436%, to $4,648,272 during 1999 from the $867,191 reported during 1998. The significant increase in sales was due principally to the successful transition from a primarily research and development company to the initial phases of a sales and marketing organization. During 1999 and 1998, the Company did not have any sales to its German distributor.

In June, 1999, the Company announced an exclusive distribution agreement with a home-consumer product distributor to manufacture and market the Company`s LazerSmile(TM) Tooth Whitening product under the name IGEA LazerWhite Tooth Whitening System. The agreement provides for a royalty to be paid to the Company and includes a minimum annual sales quota of 500,000 units. The Company had received certain prepaid royalties and had not recognized any such royalties during 1999. Prior to the distribution agreement, the Company recorded a nominal amount of sales related to its LazerSmile(TM) system. The exclusive distribution agreement expired in June, 2000. The Company intends to continue evaluating its opportunities related to the sales and marketing of its LazerSmile(TM) technology.

Gross profit was $2,852,526, or 41% of sales, in 1999, an increase of $2,805,895 from the $46,631 reported in 1998. The increase in gross profit was due to the significant increase in sales. The significant improvement in the gross margin, from 3% in 1998 to 41% in 1999, was due principally to an improved sales product mix and realized economies of scale associated with the higher sales volume.

Operating expenses decreased $2,767,975 from the $10,368,657 reported in 1998 to $7,600,682 in 1999. Operating expenses for 1999 and 1998 included non- recurring charges of $1,093,175 and $5,134,920, respectively. 1999`s non- recurring chargers related to (i) a severance agreement for a former executive officer, (ii) a consulting agreement, (iii) a write-off of assets related to product development, and (iv) a provision related to the reacquisition of distribution rights in Germany from the Company`s previous distributor. 1998`s non-recurring charges consisted of a write-off of certain purchased research and development costs related to the acquisition of certain undeveloped technology. Absent these non-recurring charges, operating expenses for 1999 would have been $6,507,507 compared to $5,233,737 for 1998, a comparative increase of $1,273,770, or 24%.

Sales and marketing expenses were $2,700,628 for 1999 compared to $1,628,821 reported for 1998, an increase of $1,071,807, or 66%. The increase was due principally to the significant rise in sales volume during 1999 and the Company`s increased marketing efforts


associated with creating public awareness of its technology and products. General and administrative expenses, absent the non-recurring charges related to the severance agreement for a former executive officer and costs related to the reacquisition of the Company`s distribution rights in Germany of $129,681 and $480,300, respectively, were $1,862,563 for 1999 compared to $1,780,015 for 1998, a modest increase of $82,548, or 5%. The increase was due principally to higher levels of administrative staffing and related personnel expenses combined with increases in various professional and administrative costs associated with the Company`s growth. Engineering and development expenses were $1,944,316 in 1999 excluding non-recurring charges related to the consulting agreement with a former principal of LSTI and the write-off of assets related to product development of $100,781 and $382,413, respectively, compared to $1,824,901 in 1998, an increase of $119,415, or 7%. The comparative increase was due principally to increased engineering staffing associated with the Company`s growth and higher engineering project expenses related to existing product enhancements and redesigns combined with new product development, in particular, the Waterlase(TM) and the Twilite(TM) laser systems.

In December, 1999, the Company licensed the undeveloped LSTI technology acquired in 1998 to a developmental company in exchange for a royalty on future sales of products encompassing such technology. The decision to license the undeveloped technology was based on the Company`s intention to focus on the marketing and further enhancement of products embodying its HydroKinetic(TM) technology, including the Waterlase(TM), and development of new products.

Interest income during 1999 was $44,666, a decrease of $12,925, or 22%, from the $57,591 reported in 1998, while interest expense increased $12,013, or 15%, to $93,647 during 1999 from the $81,634 reported in 1998. The decrease in interest income was due to lower average balances of cash and marketable securities during 1999 compared to the balances held in interest-bearing accounts in 1998. The increase in interest expense was due principally to higher average outstanding balances under the Company`s line of credit in 1999 versus 1998.


Financial Condition -

The Company`s working capital requirements have been financed over the past several years through the private placement of the Company`s equity securities. Such placements generated net proceeds of $2,450,516, $2,748,000, $3,592,800 during 2000, 1999 and 1998, respectively. The Company has also received proceeds from the exercise of stock options and warrants of $3,200,624, $85,313 and $58,426 during 2000, 1999 and 1998, respectively. In addition, the Company has a $2,500,000 short-term line of credit, of which, $708,075 is available, for the purchase of inventory.

Cash and cash equivalents increased $820,902 during 2000. Operating activities during 2000 utilized $3,778,430 of cash compared to $1,897,337 and $4,848,700 in 1999 and 1998, respectively; the increase due principally to higher receivables due to the increase in fourth-quarter sales combined with increased inventory levels required to sustain the continued growth of the Company. Investing activities utilized $1,068,862 in cash during 2000 compared to providing cash of $183,567 and $5,147 in 1999 and 1998, respectively. The use of cash during 2000 was due to increased capital expenditures principally from the purchase of the Company`s facility in August, 2000; whereas, 1999 and 1998 investing activities principally reflected cash proceeds from the sale of marketable securities for use as working capital. Financing activities provided $5,668,204 in cash during 2000 compared to $2,470,213 and $5,055,018 in 1999 and


1998, respectively. The increase in 2000 versus 1999 was due principally to a greater number of stock purchase warrants and options exercised combined with an increase in proceeds received from borrowings under the Company`s line of credit, offset by payment of a note payable and reduced proceeds from the issuance of stock in 2000 versus 1999.

Accounts receivable increased considerably in 2000 to $758,219 compared to $330,840 in 1999 due to the higher sales volume experienced in the fourth quarter for which the receivable will be collected in the first quarter of 2001.

Inventories increased significantly to $1,221,595 in 2000 compared to $658,462 in 1999. The increase is attributed principally to (i) 1999`s ending level reflecting intentional reductions in componentry related to the first generation Millennium(R) as the Company prepared for the launch of its Waterlase(TM), and (ii) increased purchase of Waterlase(TM) and Twilite(TM) components necessary to sustain the Company`s current growth and production requirements for 2001. Inventory turnover improved during 2000 to an average of 4.8 times, or every 76 days, from an average of 3.0 times, or every 121 days in 1999.

Prepaid assets increased to $179,985 in 2000 from $110,062 in 1999, an increase of $69,923 due principally to increased deposits for 2001 trade shows and seminars.

Liability under a line of credit established in December 1997 to finance inventory increased $450,000 from 1999 to 2000. The increase was a result of the Company`s need to retain higher levels of inventory to sustain its present growth pattern. The balance available for future inventory purchases, should the need arise, is $708,075; the line of credit is due to expire December 1, 2001.

The aggregate of accounts payable and accrued liabilities increased $85,580 to $2,355,240 in 2000 from $2,269,660 in 1999. The increase is attributable principally to (i) higher payroll related accruals associated with the Company`s growth and greater warranty level reserves required given the higher sales volume during 2000 offset by payments made against $480,300 in accrued expenses associated with the reacquisition of distribution rights in Germany, of which, $428,000 was converted to a note payable in March 2000, paid in September 2000.

Customer deposits for new orders increased $200,000 in 2000 reflecting the increased demand of the Company`s products during 2000 over that of 1999. All of the orders related to these deposits were shipped during the first quarter of 2001.

Capital expenditures during 2000 totaled $1,068,872 and were related primarily to the purchase of the Company`s facility (see "Liquidity and Capital Resources" below), a new sales booth and various computer workstations associated with the Company`s growth. Depreciation of fixed assets was $143,096 during 2000 compared to $90,427 in 1999. The decrease in patents, trademarks and licenses in 2000 was due solely to amortization of $22,800.

Stockholders` equity at December 31, 2000 improved to $1,056,871 from a deficit position of $939,272 in 1999. The improvement was due principally to (i) net proceeds of $2,450,516 received from a private placement in March 2000, (ii) proceeds of $3,200,624 from the exercises of certain stock options and stock purchase warrants during 2000, and (iii) the issuance of stock and warrants for services rendered aggregating $72,980. The increase to stockholder`s equity in 2000 was offset by the $3,727,977 loss for the year.


Liquidity and Capital Resources -

The Company remains dependent upon its ability to obtain outside financing either through the issuance of additional shares of its common or preferred stock or through borrowings until it achieves sustained profitability through increased sales and improved product margins. The Company`s business continues to focus on the manufacturing and marketing of its laser-based HydroKinetic(TM) tissue cutting system, the Waterlase(TM) and its new diode laser product, the Twilite(TM).

Financing the development of laser-based medical and dental devices and instruments and the operations of the Company has been achieved principally through the private placements of preferred and common stock and the exercise of stock options and warrants, though the Company has experienced significant increased sales of its laser-based products over the last two years. During the three years ended December 31, 2000, the Company raised approximately $12,136,000 of net equity funds in this manner.

Management believes that sales will continue to increase and that the Company should have sufficient capital resources to sustain it during 2001 based on its 2001 business plan. Should the Company require further capital resources during 2001, it would most likely address such requirement through a combination of sales of its products, sales of equity securities through private placements, and/or debt financings. If circumstances changed, and additional capital was needed, no assurance can be given that the Company would be able to obtain such additional capital resources.

If unexpected events occur requiring the Company to obtain additional capital and it is unable to do so, it then might attempt to preserve its available resources by deferring the creation or satisfaction of various commitments, deferring the introduction of various products or entry into various markets, or otherwise scaling back its operations. If the Company were unable to raise such additional capital or defer certain costs as described above, such inability would have an adverse effect on the financial position, results of operations, cash flows and prospects of the Company and ultimately on its ability to continue as a going-concern.

At December 31, 2000, the Company had $1,791,925 outstanding under a revolving credit agreement with a bank. The revolving credit agreement provides for borrowings of up to $2,500,000 for the financing of inventory and is collateralized by substantially all of the Company`s accounts receivable and inventories. The interest rate is fixed throughout the term of the credit agreement and is computed based upon LIBOR plus 0.5% at the time of any borrowings. At December 31, 2000, the weighted average interest rate on the outstanding balance was 7.22%. The Company is required to reduce the outstanding loan balance by an amount equal to the cost of goods sold associated with sales of inventory upon collection of sales proceeds. The current revolving credit agreement expires on December 1, 2001 at which point the Company will be required to either pay any remaining balance of the credit facility or refinance the credit facility. No assurances can be given that the Company will be able to refinance the line of credit or that the terms on which it may be able to refinance the line of credit will be as favorable as the terms of the existing line. If the Company is unable to refinance and is therefore required to repay the line of credit, the diversion of resources to that purpose may adversely affect the Company`s operations and financial condition.

The Company`s lease on its facility expired in September 2000. The lessor had notified the Company that it did not intend to renew the lease with the Company. In response,


the Company researched similar leasing rates in close proximity to its present location and determined that competitive lease rates on a similar building in structure and size were dramatically higher than the Company`s current rate. In addition, the cost of relocation to the Company would have been substantial and could have included, but not have been limited to, business interruption costs, actual moving costs and large up-front deposits typically required on new lease potentials. Accordingly, the Company entered into an agreement to purchase its existing facility with escrow closing in August 2000 at a purchase price of $1,983,000, plus direct expenses of $21,148. The Company paid $804,148 in cash and financed the remaining purchase with a $1,200,000 first trust deed mortgage. The terms of the commitment include (i) a variable interest rate of prime plus 0.25%, adjusted every three years (currently 9.75%), (ii) a term of 15 years (matures September 1, 2015), and (iii) a loan amortization term of 20 years. In March, 2001, the Company entered into an agreement to sell the facility at a fair market value of $2,350,000 with a commitment to lease the facility for a term of 5 years (with an option to extend another 5 years) at a starting monthly lease rate of $0.80 per square foot (approximately $18,624 per month) with incremental rate increases annually of no less than 2% and no more than 5% based on the increase in a local consumer price index. The Company expects to close escrow on the sale of its facility by the end of its first quarter of 2001.

Selected Quarterly Financial Data -



Quarter Ended
----------------------------------------------------------------------------
March 31, June 30, September 30, December 31,
2000 2000 2000 2000
----------------------------------------------------------------------------
Fiscal Year Ended December 31, 2000
Sales $ 1,527,026 $ 2,258,806 $ 2,187,168 $ 3,684,389
Gross profit $ 536,262 $ 1,039,053 $ 1,001,865 $ 2,251,181
Loss from operations $(1,016,081) $ (883,300) $(1,148,433) $ (585,624)
Net loss $(1,032,096) $ (887,776) $(1,164,714) $ (643,391)
Loss per share - basic and diluted $ (0.06) $ (0.04) $ (0.06) $ (0.03)

Quarter Ended
----------------------------------------------------------------------------
March 31, June 30, September 30, December 31,
1999 1999 1999 1999
----------------------------------------------------------------------------
Fiscal Year Ended December 31, 1999
Sales $ 1,785,983 $ 1,406,255 $ 2,012,824 $ 1,799,210
Gross profit $ 797,141 $ 559,128 $ 816,002 $ 680,255
Loss from operations $ (644,389) $(1,243,958) $ (865,408) $(1,994,401)
Net loss $ (669,856) $(1,245,552) $ (873,479) $(2,008,250)
Loss per share - basic and diluted $ (0.04) $ (0.07) $ (0.05) $ (0.11)

Impact of Changing Prices on Sales and Income -
The Company attempts to minimize the impact of inflation on production and operating costs through cost control programs and productivity improvements. Over the past three years, the inflation rate has been relatively low. Nonetheless, the Company has continued to experience increases in the cost of labor and some materials, in the face of requests for price reductions from customers. Due to competitive forces and market imposed selling price ceilings during 2000, the Company was unable to raise prices to its customers to pass along the cost increases experienced. The Company, however, shall continue to pursue price reductions from its materials vendors in an attempt to improve or maintain margins.



ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


The Company does not currently hold any market risk sensitive instruments for trading or other purposes.



ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA


The consolidated financial statements of the Company at December 31, 2000 and 1999 and for the three year period ended December 31, 2000, along with the notes thereto, and the Report Of Independent Accountants thereon, required to be filed in response to this Item 8, begin at page F-1 of this report.

[MicroSnake]

Press Release
SOURCE: BIOLASE Technology, Inc.
BIOLASE First Quarter Sales Increase 102 Percent
SAN CLEMENTE, Calif., April 5 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), announced today that sales for the first quarter of 2001 were $3,082,692, an increase of 102 percent over the same period last year.

Jeffrey W. Jones, BIOLASE president and CEO, stated, ``The level of our sales continues to increase at a very strong pace both domestically and internationally. Underlying this increase is the excellent reception by the dental community of our new Waterlase(TM), a laser that allows dentists to perform painless dental procedures, and the Twilite(TM), a laser for teeth whitening and soft tissue surgery.

``Additionally, we are well positioned for another excellent quarter, and we are very optimistic about continued outstanding growth for the remainder of 2001. We also believe that our sales should not be adversely affected by the global economic slowdown. Both the Waterlase and the Twilite are excellent tools for dentists to use to differentiate themselves in an increasingly competitive market. Waterlase dentists position themselves as modern, advanced technology practices offering painless laser dentistry in place of the traditional needle, anesthesia and drill.``

BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical technology company, which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase (HydroKinetic®) surgical cutting systems and other advanced laser- and non-laser-based products for the professional and consumer markets. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard- and soft- tissue dental laser technology.

The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

For further information, please contact Lori Parks, VP-Editorial, Elisa Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, of Porter, LeVay & Rose, Inc., 212-564-4700; or Jeffrey W. Jones, President and CEO of BIOLASE Technology, Inc., 949-361-1200.

[Supergeldsack]

Hi,

Gibt es keine Neuigkeiten über Biolase ?
Laut Hightecinvestor ist das Tätigkeitsfeld von Biolase eines der am schnellsten wachsenden Märkte in den USA
und die Gewinnchange liege bei 500 % in zwei Jahren. Momentan ist der Einstieg immer noch günstig da die Aktie
noch wenig bekannt ist.
Meine weiteren Favoriten die hier wenig bekannt sind : Cryolife , Loudeye und Nanophase

Frohe Ostern wünscht
SG

[MicroSnake]

BIOLASE Announces Record Sales of $1.25 Million at CDA Meeting
SAN CLEMENTE, Calif., April 25 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), today announced record sales orders at the California Dental Association (CDA), closing a total of 32 lasers valued at $1.25 million in two and one-half days, an increase of 500% over last year`s CDA sales. The CDA, held from April 20-22, is one of two state-wide meetings held in California each year. Most of the orders this year were for BIOLASE`s flagship product, the Waterlase(TM) hard and soft tissue laser. Sales also included an increase in Twilite(TM) lasers and LazerSmile(TM) Teeth Whitening systems.

Jeffrey W. Jones, BIOLASE CEO and president, said, ``I am excited by the very enthusiastic reception of our products by dentists at the CDA. The only regret I have, if I can have one after such an excellent meeting, is that we did not have a large enough booth to properly handle all of the people interested in our breakthrough products.``

Jones concluded, ``With fourth quarter 2000 sales up 105% and first quarter 2001 sales up 102% over prior year`s same quarters, and the continued growth of sales as demonstrated at the CDA, we are confident that this is going to be an outstanding year for our company. We continue to strengthen our position as the leader in dental lasers.``

BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical technology company, which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase (HydroKinetic®) surgical cutting systems and other advanced laser- and non-laser-based products for the professional and consumer markets. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard- and soft-tissue dental laser technology.

The matters discussed in this news release include forward-looking statements, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

[MicroSnake]

BIOLASE Announces Record Sales of $1.25 Million at CDA Meeting
SAN CLEMENTE, Calif., April 25 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), today announced record sales orders at the California Dental Association (CDA), closing a total of 32 lasers valued at $1.25 million in two and one-half days, an increase of 500% over last year`s CDA sales. The CDA, held from April 20-22, is one of two state-wide meetings held in California each year. Most of the orders this year were for BIOLASE`s flagship product, the Waterlase(TM) hard and soft tissue laser. Sales also included an increase in Twilite(TM) lasers and LazerSmile(TM) Teeth Whitening systems.

Jeffrey W. Jones, BIOLASE CEO and president, said, ``I am excited by the very enthusiastic reception of our products by dentists at the CDA. The only regret I have, if I can have one after such an excellent meeting, is that we did not have a large enough booth to properly handle all of the people interested in our breakthrough products.``

Jones concluded, ``With fourth quarter 2000 sales up 105% and first quarter 2001 sales up 102% over prior year`s same quarters, and the continued growth of sales as demonstrated at the CDA, we are confident that this is going to be an outstanding year for our company. We continue to strengthen our position as the leader in dental lasers.``

BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical technology company, which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase (HydroKinetic®) surgical cutting systems and other advanced laser- and non-laser-based products for the professional and consumer markets. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard- and soft-tissue dental laser technology.

The matters discussed in this news release include forward-looking statements, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

[FLOTSAM_AND_JETSAM_US]

weiters Wachstum bei BLTI

BIOLASE Technology Will Report Record Second Quarter Sales;
Sees Equally Strong Third Quarter, Remains Committed to Profitability in Fourth Quarter

SAN CLEMENTE, Calif., June 21 /PRNewswire/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI - news), reported today that strong sales growth continues, as expected. The company will report record sales exceeding $4 million for the second quarter ending June 30, 2001. Visibility into the third quarter shows continued strong growth. The company also remains confident that it will achieve profitability in the fourth quarter.

``Both domestic and international sales are benefiting from increasing demand for our technology in the dental community,`` said Jeffrey W. Jones, BIOLASE CEO and president. ``Our leading edge products have proven resistant to the economic slowdown, and our expanding sales force continues to pursue an ambitious, aggressive marketing strategy that is supported by seminars and trade shows targeted to dentists throughout the world,`` Jones added.

BIOLASE Technology, Inc. (http://www.biolase.com) is an advanced medical technology company which possesses and develops advanced dental, cosmetic, aesthetic and surgical products, including Waterlase(TM) (HydroKinetic®) surgical cutting systems and other advanced laser and non-laser based products for the professional and home consumer market. The company`s products incorporate patented and patent-pending technologies in the pursuit of painless surgery. BIOLASE is the world leader in painless hard and soft tissue dental laser technology.

[thucko]

Hallo,
vorletztes Wochenende sah ich auf N24 einen Bericht über Zahnlaser.
Gerade noch konnte ich den Schriftzug BIOLA,,, auf dem Gerät lesen.
wenn das Ding funktioniert ist da ein gigantischer Markt drin.
Doch ist es jetz schon zu spät oder gehts noch weiter ab nach Norden ?

[Kurumba]

heute wieder gute nachrichten; neues paradonthosegerät wurde zugelassen.(WATERLASE)